Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312448 | 0.90 | PIK3CD (0.55) | TGFBR1CYP1A2CYP2C9CYP2C19GAA | |
| SCHEMBL14108205 | 0.86 | KDM4E (0.69) | TGFBR1CYP1A2CYP2C9GAAKDM4E | |
| SCHEMBL4819639 | 0.83 | TGFBR1 (0.54) | TGFBR1CYP1A2CYP2C9CYP2C19GAA | |
| SCHEMBL16691118 | 0.83 | TGFBR1 (0.54) | TGFBR1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL9941410 | 0.83 | TGFBR1 (0.61) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL12928396 | 0.83 | KDM4E (0.55) | TGFBR1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL1649636 | 0.83 | TGFBR1 (0.54) | TGFBR1GAAKDM4EGLAIDO1 | |
| SCHEMBL11640185 | 0.83 | KDM4E (0.77) | CYP1A2CYP2C9CYP2C19GAAKDM4E | |
| SCHEMBL5030840 | 0.82 | TGFBR1 (0.53) | TGFBR1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL26626620 | 0.82 | TGFBR1 (0.58) | TGFBR1CYP1A2CYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4514799-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119384421-A | Certain chemical entities, compositions and methods | 沐尔佳治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885CYP1A2 3570/4885CYP2C9 3608/4885 |
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIT, PRKCH, PRKCB | TGFBR1 2522/4885CYP1A2 4079/4885CYP2C9 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.